Logo image of KDNY

CHINOOK THERAPEUTICS INC (KDNY) Stock Analyst Ratings

NASDAQ:KDNY - Nasdaq - US16961L1061 - Common Stock - Currency: USD

40.39  +0.09 (+0.22%)

After market: 40.32 -0.07 (-0.17%)

Buy % Consensus

73

ChartMill assigns a Buy % Consensus number of 73% to KDNY. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 41.11. This target is 1.77% above the current price.
KDNY was analyzed by 17 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about KDNY.
In the previous month the buy percentage consensus was at a similar level.
KDNY was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

KDNY Historical Analyst RatingsKDNY Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -80 -73 -66 -59 -52 -45 -38 -31 -24 -17 -10 -3 5 10 15

Price Target & Forecast

Price Low Median Mean High 40.3932.3240.8041.1149.35 - -19.98% 1.02% 1.77% 22.18%

Related screens

KDNY Current Analyst RatingKDNY Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8
Up and Down Grades
Date Firm Action Rating
2023-08-08 Wedbush Downgrade Outperform -> Neutral
2023-08-01 Wells Fargo Downgrade Overweight -> Equal-Weight
2023-06-21 HC Wainwright & Co. Reiterate Neutral -> Neutral
2023-06-14 Evercore ISI Group Downgrade Outperform -> In-Line
2023-06-13 SVB Leerink Downgrade Outperform -> Market Perform
2023-06-13 Stifel Downgrade Buy -> Hold
2023-06-13 HC Wainwright & Co. Downgrade Buy -> Neutral
2023-06-12 Cantor Fitzgerald Downgrade Overweight -> Neutral
2023-06-12 Guggenheim Downgrade Buy -> Neutral
2023-06-12 William Blair Downgrade Outperform -> Market Perform
2023-05-17 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-05-10 Wedbush Reiterate Outperform
2023-05-02 Cantor Fitzgerald Reiterate Overweight
2023-05-02 Guggenheim Maintains Buy
2023-03-06 Piper Sandler Initiate Overweight
2023-03-01 Guggenheim Initiate Buy
2023-02-28 Oppenheimer Maintains Outperform
2023-02-28 HC Wainwright & Co. Reiterate Buy
2023-02-21 Oppenheimer Maintains Outperform
2022-12-22 Stifel Maintains Buy
2022-12-05 Wells Fargo Initiate Overweight
2022-08-15 HC Wainwright & Co. Maintains Buy
2022-06-28 Stifel Initiate Buy
2022-05-23 SVB Leerink Maintains Outperform